New GLP-1 Pill Orforglipron May Beat Ozempic for Diabetes & Weight Loss

A novel clinical trial suggests that an experimental oral medication, orforglipron, may offer improved blood sugar control and weight loss benefits for individuals with type 2 diabetes compared to the currently available oral semaglutide, sold under the brand name Rybelsus. The findings, reported by Eli Lilly, could signal a new approach to managing the condition, though more data is needed to fully understand the drug’s profile.

Orforglipron’s Performance in the Trial

The head-to-head study, involving approximately 1,700 adults diagnosed with type 2 diabetes, randomly assigned participants to receive either one of two doses of orforglipron or one of two doses of oral semaglutide. At the study’s outset, participants had an average A1C level of 8.3 percent – a measure of long-term blood sugar control. After one year, those taking the higher dose of orforglipron experienced an average A1C reduction of 1.9 percent, while those on the higher dose of oral semaglutide saw a reduction of 1.5 percent.

Beyond blood sugar, the trial also tracked weight loss. Participants on the higher orforglipron dose lost nearly 18 pounds, representing about 8 percent of their initial body weight. In contrast, those on the higher dose of oral semaglutide lost an average of 11.5 pounds, or a little over 5 percent of their starting weight. “So on efficacy alone, orforglipron looks better,” noted Dr. Osama Hamdy, an associate professor at Harvard Medical School and medical director of the Obesity Clinical Program at the Joslin Diabetes Center in Boston.

Understanding GLP-1 Receptor Agonists

Both orforglipron and semaglutide belong to a class of medications called GLP-1 (glucagon-like peptide-1) receptor agonists. These drugs mimic the effects of a natural hormone in the gut, which helps regulate appetite and slow down digestion. This mechanism can contribute to weight loss and improved blood sugar control. They also stimulate insulin release in response to meals and reduce glucagon secretion, further aiding in blood sugar management. Maintaining stable blood sugar levels is a key goal in managing type 2 diabetes.

Side Effects and Discontinuation Rates

While orforglipron demonstrated promising efficacy, the trial also revealed a higher rate of side effects leading to treatment discontinuation. Common side effects associated with both drugs included gastrointestinal issues like nausea, diarrhea, vomiting, and indigestion. Still, almost 10 percent of participants taking the higher doses of orforglipron stopped treatment due to these effects, compared to about 5 percent in the semaglutide group. This difference highlights an important consideration for patients and clinicians.

Convenience and Flexibility with Orforglipron

One potential advantage of orforglipron lies in its flexibility regarding meal timing. Unlike Rybelsus, which requires administration first thing in the morning on an empty stomach with a small sip of water and a 30-minute waiting period before eating or drinking, orforglipron can be taken without any dietary restrictions. This can be particularly beneficial for individuals taking multiple medications, as adhering to strict timing schedules can be challenging. Dr. Melanie Jay, a professor at NYU Grossman School of Medicine, emphasized that “This makes orforglipron easier to take.” Dr. Marilyn Tan of Stanford Health Care added that coordinating medication schedules can be “cumbersome” for patients.

What the A1C Numbers Imply

The study’s findings regarding A1C levels are significant. An A1C level of 8.3 percent at the study’s start indicates suboptimal diabetes control. The American Diabetes Association generally recommends a target A1C of below 7 percent for most adults with diabetes. Both doses of orforglipron, along with the higher dose of semaglutide, helped participants achieve this target, with the lower dose of semaglutide coming close, missing the goal by just 0.1 percent. Understanding A1C levels is crucial for both patients and healthcare providers in assessing diabetes management.

Regulatory Pathway and Future Availability

Eli Lilly has announced its intention to submit an application to the U.S. Food and Drug Administration (FDA) for approval of orforglipron as a diabetes treatment. The company is also seeking approval for the drug as an obesity treatment, with an FDA decision expected this spring. The timeline for potential availability of orforglipron for diabetes remains to be seen, pending FDA review and approval.

Further Research and Clinical Implications

While the results of this trial are encouraging, Dr. Beverly Tchang, an associate professor at Weill Cornell Medicine, cautions that these findings “give us further reassurance that both orforglipron and semaglutide are excellent medications to treat type 2 diabetes.” Further research will be essential to fully characterize the long-term effects of orforglipron, including its impact on cardiovascular outcomes and other potential health benefits. Ongoing clinical trials and post-market surveillance will play a crucial role in refining our understanding of this new medication and its place in the treatment landscape for type 2 diabetes.

What’s next: The FDA will now review Eli Lilly’s application for orforglipron. The agency’s review process will involve a thorough evaluation of the trial data, manufacturing processes, and potential risks and benefits. A decision is expected in the coming months, and if approved, orforglipron could offer a valuable new treatment option for individuals struggling to manage their type 2 diabetes.